In Vitro and In Vivo Study of Combined Effect of Some Algerian Medicinal Plants and Probiotics against Helicobacter pylori

Abstract

Helicobacter pylori causes gastritis, peptic ulcers and gastric cancer and affects more than half of the world’s population. Although this infection can have serious consequences, no novel cure or remedy have been discovered, the present therapy still relies on a variety of known antibiotics and anti-secretory agents. In the present study, the potential effect of combinations between methanolic extracts of four Algerian medicinal plants, garlic (Allium sativum), red onion (Allium cepa), cumin (Cuminum cyminum L.) and fenugreek (T. foenum-graecum L.), with different strains of lactic acid bacteria against H. pylori, was investigated. Similarly, the in vivo antibacterial effect of fenugreek extract combined with Bifidobacterium breve on H. pylori colonization potential to confirm the enhanced effect of the mixture was explored. Helicobacter pylori was inhibited by all combined mixtures of extracts and probiotics with varying results. The highest anti-H. pylori activities were found in fenugreek/B. breve, cumin/B. breve, garlic/B. breve and onion/B. breve combinations with inhibition diameters of 29, 26, 23 and 25 mm, respectively. Preliminary studies on the effect of probiotics against H. pylori revealed that the inhibition was due to lactic acid and bacteriocins and it was also related to the presence of phenolic compounds in the studied plants, such as gallic acid, caffeic acid, quercetin and vanillic acid. Fenugreek extract was found to inhibit the growth of H. pylori in a concentration-dependent manner. When H. pylori-infected rats were administered B. breve, the infection rate of H. pylori was significantly reduced, while the combination of B. breve and fenugreek extract effectively inhibited H. pylori. In addition, the B. breve and fenugreek extract mixture significantly reduced gastritis in H. pylori-infected rats. These results suggest that this complex mixture may be an alternative to treating diseases caused by H. pylori infection.

Stomach microbiota in gastric cancer development and clinical implications

“…88 B. breve also demonstrated robust inhibitory effect on H. pylori in vitro and alleviated H. pylori-associated gastric inflammation in rats. 89 Thus, these findings imply that lactic acid bacteria Lactobacillus and Bifidobacterium have certain commonalities in antagonising H. pylori, which may be due to their production of lactic acid or competition for the binding sites on gastric epithelial cells.…”

Helicobacter pylori infection in humans and phytotherapy, probiotics, and emerging therapeutic interventions: a review

“…Hasna et al treated H. pylori with fenugreek extract and Bifidobacterium breve alone, and the highest IZD (inhibition zone diameter) was 16.00 ± 0.00 mm and 20.33 ± 0.58 mm, respectively. However, when the two drugs were combined to treat H. pylori, the Frontiers in Microbiology 13 frontiersin.org IZD was 28.67 ± 0.58 mm (Hasna et al, 2023). As a result, the combination began to be taken seriously.…”

Role of probiotics in managing various human diseases, from oral pathology to cancer and gastrointestinal diseases

“…These trials mostly focused on triple therapy and showed enhanced eradication rates and decreased occurrence of adverse effects when it was used in combination with different probiotics (Wang et al, 2023a). There are many alternative eradication therapies based on probiotics as adjuvant agents (Penumetcha et al, 2021), such as the combination of multiple antibiotic-resistant lactic acid bacteria preparations and Vonoprazan (Kakiuchi et al, 2020), capsules containing four probiotics (Telaku et al, 2022) and combined mixtures of medicinal plants extracts with different probiotic strains (Hasna et al, 2023).…”